- Home
- TRC vs ALT Comparison
TRC vs ALT Comparison
Compare TRC & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TRC | ALT |
|---|---|---|
| Founded | 1843 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 517.1M | 415.3M |
| IPO Year | 1995 | 2005 |
Fundamental Metrics
Financial Performance| Metric | TRC | ALT |
|---|---|---|
| Price | $19.26 | $3.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 103.1K | ★ 2.8M |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.37 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $37,830,000.00 | $41,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $15.04 | $2.87 |
| 52 Week High | $19.61 | $7.73 |
Technical Indicators
Market Signals| Indicator | TRC | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 62.94 | 43.15 |
| Support Level | $18.10 | $2.91 |
| Resistance Level | $19.33 | $4.25 |
| Average True Range (ATR) | 0.48 | 0.18 |
| MACD | -0.03 | 0.04 |
| Stochastic Oscillator | 75.68 | 54.76 |
Price Performance
Historical ComparisonAbout TRC Tejon Ranch Co
Tejon Ranch Co is a diversified real estate development and agribusiness company. It has six reporting segments: Real Estate - Commercial/Industrial, Multifamily, Real Estate - Resort/Residential, Mineral Resources, Farming, and Ranch Operations.
About ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.